Clinical trial NCT02687321: The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Official title: The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer: First Prospective Multicentre Observational Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ovarian Neoplasms
Lead sponsor: Brno University Hospital
Sponsor class: OTHER
Collaborators: name: University Hospital Pilsen
First posted: 2016-02-22
Enrollment: 150
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with histologically confirmed advanced epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment.

Brief summary: To evaluate and to compare the effectiveness of CA-125 and HE4 serum levels in epithelial ovarian cancer (OC) in follow-up in terms of time to detection of elevation after the end of the first line treatment. To evaluate the lead-time of the rise of marker levels before epithelial OC recurrence diagnosis by Computed tomography (CT) imaging method. To evaluate the appropriate HE4 cut-off value for follow-up of patients after the treatment of ovarian, Fallopian tube and primary peritoneal cancer.

Detailed description: Ovarian cancer (OC) is the second most common gynaecologic cancer and the leading cause of death from gynaecologic malignancy among women in industrialized countries. The global incidence in both developed and developing countries can be estimated as 165,000 new cases per year. A heavy difference in prognosis exists between the early-stage disease FIGO I-II (International Federation of Gynaecology and Obstetrics and the advanced stages (FIGO III-IV). Unfortunately, at present, we do not have an effective screening strategy for this malignancy; most (70-80%) of the cases are diagnosed as advanced-stage disease, and this explains the high mortality rate. These aggressive features of the OC encouraged in recent years a big effort in order to find new strategies for early diagnosis of OC. These studies focused dominant on new markers and diagnostic algorithms among new markers. HE4 is one of the most promising. It is a protein initially identified in the epithelium of the distal epididymis and may be involved in sperm maturation. Despite its wide distribution, it is overexpressed only in pathological tissue, and it has demonstrated good sensitivity and specificity in detecting OC, overcoming the traditional role of CA-125. Despite an aggressive upfront treatment strategy (surgery plus chemotherapy), leading to clinical remission in more than 80% of patients, the relapse-free survival varies from 95.8% (for early FIGO stages) to 33.6% (for advanced stages) at 2 years. At present, periodical evaluation of CA-125 combined with physical examination is the recommended strategy for OC follow-up, typically every 3 to 4 months in the first 2 years after primary treatment and then every 6 months until the fifth year. Five years' overall survival rate, however, is 49.7% (ranging from 83%-89% in stage I OC to 18% in stage IV). New markers should be tested in the follow-up of patients with OC to improve the surveillance program performance: the challenge is to try to anticipate the diagnosis of OC recurrence and to translate this early diagnosis of relapse in a survival improvement. Few studies only are available to date about HE4 use in follow up of ovarian cancer. All of these studies analyzed a small number of women (8-73). HE4 was shown as an earlier indicator of recurrence of OC with respect to CA-125, with a lead-time of 5 to 8 months. Only 1 prospective controlled study has been published. In this study the sensitivity and specificity of HE4, alone or in association with other markers (CA-125, CA-72-4), seems to be higher in the diagnosis of the OC relapse with respect to CA-125 alone. The other side of the question is whether the patient is advantaged by an earlier detection of the recurrent disease, in terms of overall survival, disease-free survival, and quality of life. Early detection and treatment of cancer in general or its recurrence are usually associated with better outcomes for patient, this being the rationale behind screening programs and follow-up strategies. In OC follow-up, periodical CA-125 evaluation can detect recurrence of cancer about 5 months before clinical signs or symptoms. At the same time, we have to remind, that treatments of relapsing OC are rarely curative and have heavy adverse effects, and elevation of CA-125 is often cause of anxiety in patients undergoing follow-up. The main study, that tried to clarify the role of CA-125 in OC follow-up was MRC OV05/EORTC (European Organisation for Research and Treatment of Cancer) 55955 trial a randomized study comparing early versus delayed treatment in women with relapsed OC. Patients in the delayed treatment group were treated only at clinical or symptomatic relapse. Women assigned to early treatment started chemotherapy 4.8 months earlier than those allocated to the delayed treatment. With a median follow-up of 56.9 months, there was no evidence of a difference in overall survival between the 2 groups. In particular, the results provided no evidence of an improved overall survival or a better quality of life in the early treatment group. The authors' explanation for these findings was that the lead-time between CA-125 rise and the clinical recurrence could be too short for chemotherapy to give a beneficial effect. At present, periodical evaluation of CA-125 combined with physical examination is the recommended strategy for OC follow-up, typically every 3 to 4 months in the first 2 years after primary treatment and then every 6 months until the fifth year. Five years' overall survival rate, however, is 49.7% (ranging from 83%-89% in stage I OC to 18% in stage IV).

Eligibility criteria: Inclusion Criteria:

* advanced ovarian cancer, stage FIGO III and IV
* histology types: high-grade serous, low-grade serous, endometrioid, clear cell, undifferentiated
* completed ovarian cancer surgery and platinum-based chemotherapy

Exclusion Criteria:

* positivity of tumor markers CA 125 and HE4 during study enrollment
* signs of cancer at computed tomography scan during study enrollment

Primary outcomes:
measure: Serum levels of tumor marker CA-125
timeFrame: two years after study enrollment
measure: Serum levels of tumor marker HE4
timeFrame: two years after study enrollment
Secondary outcomes:
measure: Ovarian cancer recurrence diagnosed by computed tomography scan
timeFrame: two years after study enrollment
Other outcomes:
Locations:
city: Brno
country: Czechia
facility: Brno University Hospital
city: Ceske Budejovice
country: Czechia
facility: Hospital Ceske Budejovice
city: Hradec Králové
country: Czechia
facility: Faculty Hospital in Hradec Králové
city: Jihlava
country: Czechia
facility: Hospital Jihlava
city: Pilsen
country: Czechia
facility: Faculty Hospital Pilsen
city: Prague
country: Czechia
facility: General Hospital Prague
city: Zlin
country: Czechia
facility: Regional Hospital Pilsen
city: Debrecen
country: Hungary
facility: University of Derecen
city: Kielce
country: Poland
facility: Swietokrzyskie Cancer Center
city: Kraków
country: Poland
facility: Cancer Center, M.Sklodowska-Curie Memorial Institute
city: Lublin
country: Poland
facility: Medical University of Lublin
city: Szczecin
country: Poland
facility: Pomeranian Medical University
city: Warsaw
country: Poland
facility: Medical University of Warsaw
city: Wroclaw
country: Poland
facility: Lower Silesian Cancer Center
city: Bratislava
country: Slovakia
facility: Institute of Oncology, Bratislava
city: Bratislava
country: Slovakia
facility: National Institute of Oncology, Bratislava
city: Bratislava
country: Slovakia
facility: University Hospital Bratislava
city: Trencin
country: Slovakia
facility: FN Trencín
city: Madrid
country: Spain
facility: La Paz University Hospital. Madrid
city: L'viv
country: Ukraine
facility: Lviv State Regional Oncological Center
Study officials:
affiliation: University Hospital Brno
name: Vit Weinberger, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Pilsen
name: Jiri Presl, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: